Yifeng Pharmacy Chain (603939): UBS views Yifeng’s equity incentive plan and new vice-president appointment positively

Overview

This UBS fast take assesses Yifeng Pharmacy Chain’s newly announced equity incentive plan and appointment of Lei Yu as vice president. UBS characterizes the developments as positive and maintains its Buy rating and Rmb33.50 12-month target price.

Core views

UBS views Yifeng’s new equity incentive plan positively. The plan requires at least 10% growth in net profit attributable to parent in 2026 and at least 26.5% growth in 2027, both measured against 2025. At the latest close, UBS states that these targets imply roughly 15x and 13x 2026E and 2027E P/E, respectively. The incentive structure therefore ties employee rewards to specified profit-growth outcomes over the next two years. The company also appointed Lei Yu, formerly CEO of Dingdang Health, as vice president. UBS presents the appointment alongside the incentive announcement as a positive development, without providing additional operating forecasts tied specifically to the executive change. UBS retains a 12-month Buy rating and a Rmb33.50 price target, compared with a Rmb23.01 closing price on 29 September 2026. Its forecast-return table shows 45.6% forecast price appreciation, a 3.4% forecast dividend yield, and a 49.0% forecast stock return, against a 6.7% market-return assumption and therefore a 42.3% forecast excess return. UBS derives its target price using DCF methodology. The report’s financial projections show revenue rising from Rmb24,433m in 2025 to Rmb25,717m in 2026E and Rmb28,198m in 2027E, while UBS net earnings rise from Rmb1,693m to Rmb1,912m and Rmb2,197m. Diluted EPS is projected at Rmb1.58 in 2026E and Rmb1.81 in 2027E, with EBIT margin forecast to improve from 10.0% in 2025 to 10.4% and 10.8%, respectively. The report describes Yifeng as a leading national Chinese drugstore chain operating across nine provinces, with leading sales market share in six and a strategy centered on greater store density in existing regions and entry into new markets every two to three years.

Analysis framework

UBS evaluates the announced incentive-plan profit targets and management appointment, places them alongside its earnings forecasts and valuation multiples, and values the company using a discounted cash flow approach to derive the 12-month price target.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow methodology

  UBS states that it derives the Rmb33.50 price target using DCF, which values the company from projected future cash flows discounted to a present value.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Yifeng Pharmacy Chain (603939.SS)

  Primary covered company; UBS rates the shares Buy following the equity incentive-plan and management announcements.

  Strengths

  The plan sets explicit 2026 and 2027 profit-growth targets; Yifeng has leading sales market share in six of the nine Chinese provinces it covers.

  Comparison

  The targets imply approximately 15x 2026E and 13x 2027E P/E at the latest close.

  Risks

  Policy changes, operational-regulatory failures, intensifying competition, and migration of pharmacy purchases to online channels.

Key data

• Equity incentive target: 2026At least 10% net profit attributable to parent growth versus 2025Plan performance target.
• Equity incentive target: 2027At least 26.5% net profit attributable to parent growth versus 2025Plan performance target.
• 12-month price targetRmb33.50UBS DCF-derived target.
• Share priceRmb23.01As of 29 September 2026.
• Forecast stock return49.0%Comprises 45.6% forecast price appreciation and 3.4% forecast dividend yield.
• 2026E / 2027E diluted EPSRmb1.58 / Rmb1.81UBS estimates.

Impact & implications

UBS considers the incentive targets and leadership addition supportive developments within its existing Buy case. The report’s valuation and return framework indicates that UBS sees material forecast return relative to its market-return assumption.

Risks

• Changes in medical-insurance reimbursement scope or product reimbursement prices could affect drugstore traffic and margins; policy requirements could also raise expansion and operating costs.
• Regulatory breaches in drugstore operations could lead to loss of state-insurance payment eligibility or revocation of operating licenses.
• Accelerating industry consolidation and regional leaders could hinder cross-region expansion and intensify competition among leading chains.
• Lower online pharmaceutical prices and changing purchasing habits could shift offline traffic to e-commerce.